You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Why VYXEOS for sAML treatment?

A variety of factors are considered when determining whether or not VYXEOS (vix-e-ose) is the right treatment. These factors may include your age, your overall health, and whether you have a confirmed diagnosis of secondary acute myeloid leukemia (sAML), specifically therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Only a healthcare provider can decide if VYXEOS is the best course of treatment.

See the treatment success story of a patient diagnosed with AML-MRC.

Individual results may vary.

Please see Important Safety Information, including Boxed Warning for VYXEOS at the bottom of this page and the full Prescribing Information.


How VYXEOS may help

VYXEOS provides a chance to live longer and allows you to spend less time connected to an intravenous (IV) infusion line during treatment compared to the standard chemotherapya treatment

In a clinical trial including older adults with t-AML or AML-MRC in which 153 people received VYXEOS and 156 people received the standard chemotherapya treatment for AML:

In this clinical trial, people with sAML treated with VYXEOS lived longer than those treated with standard chemotherapy.a

Median survival timeb

Estimated survivalc at 1 year after the start of treatment

In this clinical trial, more people with sAML treated with VYXEOS achieved a complete responsed than those treated with standard chemotherapya

Secondary AML patients who achieved a complete responsed

In this clinical trial, more people with sAML treated with VYXEOS received transplant after treatment

Secondary AML patients who received a hematopoietic stem cell transplant (HSCT)

VYXEOS may cause serious side effects, including:

Temp icon

Fever, signs of infection, or bruising or bleeding which can result in serious infection and/or bleeding and possibly lead to death. You should tell your doctor about new onset fever or symptoms of infection or if you notice signs of bruising or bleeding.

Heart icon

Signs of heart failure such as shortness of breath or trouble breathing; swelling or fluid retention, especially in the feet, ankles, or legs; or unusual tiredness.

Skin damage icon

Skin damage which can occur if VYXEOS leaks out of the vein. Tell your doctor right away if you experience symptoms of burning, stinging, or blisters and skin sores at the injection site.

Caution icon

Signs of hypersensitivity reactions, including anaphylaxis such as difficulty breathing, severe itching, skin rash and hives, or swelling of the face, lips, mouth, or tongue. Seek immediate medical attention if you develop any of these signs or symptoms.

These are not all of the possible side effects of VYXEOS. Be sure to speak to your healthcare team about any side effects you have.

Please see full Prescribing Information, including BOXED Warning, and discuss with your doctor.


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.